Alvotech (ALVO)
NASDAQ: ALVO · Real-Time Price · USD
3.520
+0.220 (6.67%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Alvotech Revenue
In the year 2025, Alvotech had annual revenue of $588.90M with 19.70% growth. Alvotech had revenue of $168.90M in the quarter ending December 31, 2025, with 10.14% growth.
Revenue (ttm)
$588.90M
Revenue Growth
+19.70%
P/S Ratio
1.87
Revenue / Employee
$460,441
Employees
1,279
Market Cap
1.10B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Perrigo Company | 4.25B |
| Evotec SE | 925.65M |
| ANI Pharmaceuticals | 883.37M |
| Tilray Brands | 858.28M |
| Collegium Pharmaceutical | 780.57M |
| Pacira BioSciences | 726.41M |
| Amphastar Pharmaceuticals | 719.89M |
| Ironwood Pharmaceuticals | 296.15M |
ALVO News
- 4 days ago - Alvotech to Report Financial Results for the First Quarter of 2026 - GlobeNewsWire
- 4 weeks ago - Alvotech files Annual Report with the SEC - GlobeNewsWire
- 4 weeks ago - Alvotech Publishes 2025 Annual Report - GlobeNewsWire
- 5 weeks ago - Alvotech Q4 2025 and Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Alvotech Announces Increase in Number of Own Shares - GlobeNewsWire
- 2 months ago - Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio® - GlobeNewsWire
- 3 months ago - Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates - GlobeNewsWire